Duopharma menang kontrak RM155.28 juta bekal insulin kepada Kementerian Kesihatan
KUALA LUMPUR: Anak syarikat milik penuh Duopharma Biotech Bhd, Duopharma (M) Sdn Bhd (DMSB) memperoleh kontrak bernilai RM155.28 juta daripada Kementerian Kesihatan (KKM) bagi membekalkan produk insulin manusia rekombinan dan pen insulin boleh guna semula kepada fasiliti kesihatan kerajaan. Dalam makluman kepada Bursa Malaysia hari ini, syarikat farmaseutikal itu berkata DMSB menerima dan bersetuju dengan surat setuju terima (LOA) daripada kerajaan bagi kontrak selama tiga ta
Duopharma (M) Sdn Bhd, a subsidiary of Duopharma Biotech Bhd, has secured a three-year contract worth RM155.28 million from the Ministry of Health. The agreement, effective from June 3, 2026, to June 2, 2029, involves the supply of recombinant human insulin and reusable insulin pens to government health facilities. This initiative aims to support the management of diabetes in Malaysia, a condition affecting an estimated 4.75 million people, with a significant portion relying on government healthcare for insulin treatment.
This contract is significant as it addresses a critical healthcare need for a large diabetic population in Malaysia, potentially improving access to essential diabetes medication.
📌 Kaynak
Bu özet Berita Harian (MY) kaynağından otomatik derlenmiştir. Tamamı için orijinal habere gidin.
Orijinal haberi oku →